09:50 AM EST - IntelGenx Corp. : Announced that its previously undisclosed development candidate, Buprenorphine Buccal Film, for which an abbreviated new drug application has been filed by Chemo Research SL through its agent and affiliate Xiromed LLC , has received a U.S. Food and Drug Administration Generic Drug User Fee Act date of April 28, 2023. IntelGenx Corp.
shares T.IGX are trading unchanged at $0.20.
